The chapter discusses how Millennium Pharmaceuticals, Inc. has experienced growth over time by creating and sustaining corporate values. Incorporated in January 1993, Millennium Pharmaceuticals was among a group of second-generation biotechnology companies whose business plan was devoted to genomics. Millennium started by associating with key scientists such as Massachusetts Institute of Technology's (MIT) Eric Lander, the head of the largest genome center in the United States. The company continued to be very successful in hiring or consulting with top-level scientists, and acquiring or licensing state-of-the-art technologies, all of which facilitated the process of gene discovery, gene function analysis, and identification of drug targets. Millennium's focus on values and ethics was instilled in the company by its founder, Mark Levin. As part of its commitment to its core business, Millennium has been dedicated to the ideals of corporate values and ethics. This vision began with Mark Levin, who started his career as a chemical and biomedical engineer at Eli Lilly. Partnering with pharmaceutical companies was fundamental to Millennium's early success, and the approach to partnering included aspects of its core values. Steven Holtzman, who negotiated the company's earliest agreements with large pharmaceutical companies, believed that the company's focus on values and ethics was one reason for Millennium's attractiveness to these companies.